Stephens Investment Management Group LLC Purchases 186,670 Shares of Protagonist Therapeutics, Inc. $PTGX

Protagonist Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Stephens Investment Management Group increased its Protagonist Therapeutics stake by 66.2% in the third quarter, adding 186,670 shares to hold 468,502 shares, worth about $66 million. Institutional investors collectively own 98.63% of the company.
  • Protagonist reported quarterly EPS of $3.07, beating the $2.50 consensus, and revenue of $274.4 million versus estimates of $238.5 million. Analysts’ average rating is “Buy,” with an average price target of $166.67.
  • Company insiders sold 186,347 shares worth about $26.9 million over the past 90 days; one CFO sale was made under a pre-arranged Rule 10b5-1 plan.
  • MarketBeat previews the top five stocks to own by December 1st.

Stephens Investment Management Group LLC lifted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 66.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 468,502 shares of the company's stock after purchasing an additional 186,670 shares during the quarter. Stephens Investment Management Group LLC owned about 0.72% of Protagonist Therapeutics worth $66,007,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Protagonist Therapeutics in the second quarter valued at $1,263,535,000. Johnson & Johnson purchased a new position in Protagonist Therapeutics in the 2nd quarter valued at $300,220,852. Jupiter Topco LLC purchased a new position in shares of Protagonist Therapeutics in the second quarter worth about $261,039,000. Bank of America Corp DE purchased a new stake in Protagonist Therapeutics during the 2nd quarter valued at about $162,357,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Protagonist Therapeutics in the 2nd quarter valued at about $117,783,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Insider Activity at Protagonist Therapeutics

In related news, insider Arturo Molina sold 2,718 shares of the company's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $124.65, for a total value of $338,798.70. Following the completion of the sale, the insider directly owned 81,397 shares of the company's stock, valued at $10,146,136.05. This represents a 3.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Asif Ali sold 58,629 shares of the company's stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the sale, the chief financial officer directly owned 59,003 shares of the company's stock, valued at $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 186,347 shares of company stock valued at $26,891,786 over the last ninety days. Insiders own 5.19% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. TD Cowen increased their price target on Protagonist Therapeutics from $155.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday, October 21st. Weiss Ratings upgraded Protagonist Therapeutics from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, November 4th. Leerink Partners began coverage on Protagonist Therapeutics in a research note on Monday, October 12th. They issued an "outperform" rating and a $190.00 target price for the company. BMO Capital Markets boosted their price target on shares of Protagonist Therapeutics from $178.00 to $190.00 and gave the company an "outperform" rating in a research report on Tuesday, September 1st. Finally, Citigroup upped their price objective on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a "buy" rating in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the stock. According to data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of "Buy" and an average price target of $166.67.

Get Our Latest Research Report on Protagonist Therapeutics

Protagonist Therapeutics Trading Up 2.0%

NASDAQ:PTGX opened at $127.16 on Thursday. Protagonist Therapeutics, Inc. has a 12-month low of $77.00 and a 12-month high of $160.81. The firm has a market cap of $8.30 billion, a PE ratio of 26.94 and a beta of 1.21. The stock has a fifty day moving average price of $139.10 and a 200 day moving average price of $119.78.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating the consensus estimate of $2.50 by $0.57. The firm had revenue of $274.41 million for the quarter, compared to analyst estimates of $238.49 million. Protagonist Therapeutics had a return on equity of 42.83% and a net margin of 62.04%. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current year.

About Protagonist Therapeutics

(Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company's programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Read More

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Protagonist Therapeutics Right Now?

Before you consider Protagonist Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.

While Protagonist Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines